NDAORALTABLETPriority Review
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16
Mechanism of Action
Fibroblast Growth Factor Receptor Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
Started Mar 2023
90 enrolled
Muscle-invasive Bladder Cancer
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
Started Mar 2023
5 enrolled
Urinary Bladder NeoplasmsReceptors, Fibroblast Growth Factor
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Started Apr 2022
235 enrolled
Non-Muscle Invasive Bladder Neoplasms
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
Started Apr 2020
3 enrolled
Castration-Resistant Prostate CarcinomaDouble-Negative Prostate CarcinomaMetastatic Prostate Carcinoma+4 more
A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants
Started Mar 2020
15 enrolled
Healthy
Loss of Exclusivity
LOE Date
Feb 2, 2038
145 months away
Patent Expiry
Feb 2, 2038
Exclusivity Expiry
Jan 19, 2027